May 8, 2024In some studies examining small animals exposed to glucagon-like peptide-1 receptor agonists in pregnancy, there has been evidence of adverse outcomes in the offspring, including decreased fetal growth, skeletal and visceral anomalies, andembryonicdeath. Although there are no prospective studies in humans, case reports, cohort studies, and population-based studies have not shown a pattern of ...
These findings underscore the crucial role of modulating circulatingGLP-1levels in maternal adaptation, emphasizing the inhibitory effects of excessiveGLP-1receptor activation on both placentaldevelopmentandfetal growth. NEW & NOTEWORTHY Our study reveals a progressive decline in maternal blood glucagon-like peptide1(GLP-1) concentration.
Dec 1, 2025Primary endpoint is maternal and fetal complications during pregnancy, labor, and delivery after exposure toGLP-1receptor agonists.A systematic searā¦
This prospective cohort study aims to examine ovarian stimulation cycle parameters, retrieval outcome data and rates of procedure complications in patients with recent use ofGLP-1agonists prior to or during their oocyte or embryo cryopreservation cycle.
Recent results provided "reassuring" early evidence that taking noninsulin antidiabetic medications (ADMs) for type 2 diabetesāincluding glucagon-like peptide1(GLP-1) receptor agonistsāduring early pregnancy is not linked with a greater risk of major birth defects than taking insulin. The researchers followed up the children of more than 50 000 pregnant people in 6 countries for1...
What is the key question? What is the current scientific data on the safety ofGLP-1agonists and SGLT2 inhibitors during pregnancyand/or lactation? What are the new findings?GLP-1agonists affect fetal weight, growth and skeletal ossification in animal studies, although liraglutide and exenatide do not cross the placenta.
Abstract Aims/hypothesis Glucagon-like peptide1(GLP-1) agonists and sodium-glucose co-transporter-2 (SGLT2) inhibitors are novel drugs which have recently seen rapid uptake in the treatment of type 2 diabetes and obesity. The paucity of data regarding their safety during pregnancy and lactation causes a dilemma for the physician. The aim of the present study was to systematically review all ...
Mar 1, 2025The prevalence of type 2 diabetes mellitus (T2DM) and obesity is increasing in young adults, posing significant risks around pregnancy. Obesity also impacts on fertility and the co-existence of polycystic ovarian syndrome increases the prevalence of cardiovascular metabolic risk factors. There has been a renewed interest in glucagon-like peptide-1 receptor agonists (GLP-1RA) in this context ...
Glucagonālike peptideā1 (GLPā1) receptor agonists (GLPā1RAs) are used for obesity and PCOS and show promise in alleviating female infertility. In the past, weight loss was believed to address hormonal imbalances, leading to the restoration of ovulation. However, the impact of GLPā1RAs on endometrial receptivity, embryo implantation, and earlydevelopmentremains to be fully ...
May 8, 2024In some studies examining small animals exposed to glucagon-like peptide-1 receptor agonists in pregnancy, there has been evidence of adverse outcomes in the offspring, including decreased fetal growth, skeletal and visceral anomalies, andembryonicdeath.
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) have become firmly established in the treatment of type 2 diabetes and obesity, disorders frequently associated with diminished reproductive health. Understanding of the role ofGLP-1andGLP-1RAs in reproduction is currently limited and largely unaddressed in clinical studies.
Caenorhabditis Genetics Center (CGC) Strains carrying this gene Ā«12 3 4 5 Ā»
We show that a second maternal gene, apx-1, functions withglp-1only in the specification of the ABp fate and that apx-1 can encode a protein homologous to the Delta protein of Drosophila. Our results suggest how interactions mediated byglp-1andapx-1 contribute to the establishment of the dorsal-ventral axis in the early C. elegans embryo.
Description The C. elegans genome encodes two Notch receptors,GLP-1andLIN-12 (Greenwald and Kovall, 2013). These receptors function in multiple tissues to regulatedevelopment, behavior, and reproduction.GLP-1controls cell fate decisions in the germline (Kimble and Seidel, 2013) and early embryo (Priess, 2005). LIN-12 controlsdevelopmentof the vulva (Greenwald, 2005; Sternberg, 2005 ...
In C. elegans, theglp-1gene encodes a membrane receptor that is required for anterior cell fates in the early embryo. We report thatGLP-1protein is localized to anterior blastomeres in 2- to 28-cell embryos. By contrast,glp-1mRNA is present in all blastomeres until the 8-cell stage. Furthermor ā¦
The stereotype cleavage pattern of the early embryo results in invariant cell-cell contacts that guarantee the specificity of the inductions. Both inductions are affected in embryos mutant forglp-1suggesting that in both casesglp-1is involved in the reception of the signal.
Evidence supporting the use of glucagon-like peptide-1 (GLP-1) analogues to pharmacologically treat disorders beyond type 2 diabetes and obesity is increasing. However, little is known about how activation of theGLP-1receptor (GLP-1R) during ...
The stereotype cleavage patterns of the early embryo results in invariant cell-cell contacts that guarantee the specificity of the inductions. Both inductions are affected in embryos mutant forglp-1suggesting that in both casesglp-1is involved in the reception of the signal.
Aug 29, 2024However, larger studies on the influence of early pregnancyGLP-1receptor agonist use on neonatal outcomes and malformations have been lacking. This review aimed to systematically analyse the evidence regardingGLP-1receptor agonist use during early pregnancy and its impact on congenital malformations.
In females, loss ofGLP-1leads to a severe block in germ celldevelopmentas early as E17.5. Together, these data identifyGLP-1as a critical nuclear repressor in somatic cells of the gonad that is required for germ celldevelopment,andhighlight the importance of somatic-germ cell interactions in the regulation of this critical process.
Oct 29, 2025The three prenataldevelopmentstages (germinal,embryonic,andfetal) involve the growth and changes that take place from conception to birth.
In contrast, glp-1/glp-1 homozygous mothers produce onlyabnormalprogeny irrespective of the genotype of the embryo (glp-1/+, or glp->lglp-1). This is a strict maternal effect lethality, because a paternally contributed wild-type chromosome (+) does not rescue theembryonicdetect.
In this study, we characterize theembryonicgerm cell loss inGLP-1null mice. Quantitative PCR demonstrates that ovarianGlp-1mRNA is expressed in a bimodal pattern during embryogenesis, peaking at E13.5-14.5 and again at birth. In contrast, adult ovaries express low but detectable levels ofGlp-1mRNA.
Expression of GATA-like protein-1 (GLP-1) in ovarian somatic cells is required for normal fertility in female mice, asGLP-1deficiency leads to the absence of oocytes at birth. However, the timing and nature of this germ cell loss is not well understood. In this study, we characterize theembryonicgerm cell loss inGLP-1null mice.
GLP-1andits receptors were identified in mES and duringembryonicdevelopment. In pluripotent mES,GLP-1modified the expression of endodermal, ectodermal, and mesodermal gene markers as well as sonic hedgehog, noggin, members of the fibroblast and hepatic growth factor families, and others involved in pancreaticdevelopment.